According to new research published in the “Journal of Psychopharmacology,” individuals who take microdoses of psychedelic drugs report improvements in creativity and mood. Rotem Petranker, the study author, and his colleagues observed a growth in public interest with regard to consuming microdoses of psilocybin or LSD. This purportedly helps enhance emotional or cognitive functioning. However, this has not been proven because of insufficient research.
Petranker, who is the associate director of the University of Toronto’s Psychedelic Studies Research Program explains that any individual who is interested in mapping out consciousness should consider psychedelics as a useful perspective. He adds that at the beginning of his research, there was no published research that existed on microdosing psychedelics.
Using prior knowledge about building surveys to do their research, Petranker and his colleague, Thomas Anderson, investigated the difference between nonmicrodosers and microdosers, with a focus on creativity and mental health.
Prior studies done by the researchers, based on 278 individuals discovered that those who ingested small doses of psychedelic substances reported an improvement in creativity, focus and moods.
The new study the researched conducted extended and reproduced those results through the use of data from the Annual Global Drug Survey 2019. The survey incorporated the responses of 123,814 individuals from 215 countries. The research results noted that 2,832 participants admitted to having microdosed psilocybin in the last 12 months, 4,783 admitted to microdosing on LSD in the last 12 months, and 862 reported to have microdosed on both of the above psychedelic drugs during the same time period. The most common benefits were reported to be improved creativity and mood. Improved social benefits and energy were more commonly reported than had been expected while improved focus was less commonly cited.
Additionally, a majority of the participants reported that they experienced no side effects. Those who did reported impaired focus and physiological discomfort when microdosing on psilocybin, and mental confusion and impaired energy when microdosing on LSD. On a general scale, however, the benefits can be seen to outweigh the downsides.
The researchers also discovered a diversity of opinions in regards to whether it was more beneficial to take a higher dose or microdose of psychedelics. A quarter of the participants reported that they found both to be equally beneficial, an additional one-third found microdosing to be more beneficial, while two-fifths stated that higher doses were more beneficial in comparison to microdosing.
Despite the highly informative study, the researchers still believe we are a long way from learning everything that we need to know about microdosing in particular and, on a larger scale, psychedelics.
Pure Extracts Technologies Inc. is a player in the psychedelics industry that you should watch. This British Columbia-headquartered company focuses on extracting compounds from plants, with an emphasis on hemp and cannabis, as well as medicinal and functional mushrooms.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.